Rethinking addiction in the age of Ozempic

Episode Summary

Executive Summary: This episode explores GLP-1 drugs like Ozempic/Wegovy as a possible breakthrough for addiction treatment, alongside their limits, side effects, costs, and long-term unknowns. Through medical reporting and lived-experience recovery stories, it argues that addiction is biological, psychological, and social—best addressed with medication, empathy, self-compassion, and community, not stigma or quick fixes.

Main Topics: GLP-1s as a potential addiction treatment (Priority: 5/5): Dr. Dhruv Kular explains growing evidence that GLP-1 drugs may reduce cravings for alcohol, nicotine, opioids, and other compulsive behaviors by affecting reward pathways and possibly gut-brain signaling. Mary’s recovery story (Priority: 5/5): A participant in a semaglutide trial experienced reduced alcohol cravings, major weight loss, and broader life changes, showing how the drug may alter behavior beyond appetite control. Limits and risks of GLP-1s (Priority: 5/5): The discussion emphasizes that these medications are not a universal cure: adherence is difficult, side effects and costs are significant, and some people may experience emotional blunting or regain cravings after stopping. Addiction as a multifactorial condition (Priority: 4/5): Eric Zimmer and Kular frame addiction as shaped by biology, trauma, psychology, and social environment, arguing against moral blame and simplistic solutions. Recovery as a skill and a system (Priority: 4/5): Zimmer stresses that behavior change can be learned through self-compassion, repetition, peer support, and rebuilding life structures such as health, relationships, and purpose. Screen addiction and modern moderation (Priority: 3/5): Naima Raza extends the episode’s theme to digital life, arguing that modern technology intensifies compulsive behavior and that pause, curiosity, and real-world conversation are antidotes.

Key Arguments: GLP-1s may function as 'moderation molecules' by dampening reward-driven cravings without eliminating desire entirely. The same drug class may help across multiple addictions, which is unusual because traditional addiction medications are typically substance-specific. Addiction has long been understood as biological, but GLP-1 research could deepen that understanding by showing shared mechanisms across food, alcohol, nicotine, and other compulsions. The exact mechanism remains unclear; the drugs may act through dopamine/reward circuitry and/or gut-brain communication. These drugs are not a silver bullet: many people stop taking them within a year, and access and cost remain major barriers. For some users, benefits may come with tradeoffs like rapid weight loss, GI effects, or a blunted sense of pleasure. Recovery works best as a combination of tools—medical treatment, therapy, peer support, behavior change, physical health, and emotional work. Shame and self-blame often worsen addiction; self-compassion and curiosity about setbacks improve the odds of change. Modern environments overload people with food, content, and stimulation, making moderation harder and increasing the appeal of pharmacological help.

Data Points: Americans age 12+ with a substance use disorder: nearly 1 in 6 - Used to frame the scale of addiction in the U.S. Time since FDA last approved a medication for alcohol use disorder: more than 20 years - Highlights why GLP-1s are generating excitement. Weight loss in Mary’s trial: 55 pounds in 5 months - Her semaglutide/Ozempic experience during the clinical trial. Calorie intake during Mary’s treatment: 300–500 calories per day on some days - Shows how strong the appetite suppression became. People coming off GLP-1s within a year: half or more - Reported as a major real-world adherence challenge. Estimated monthly sticker price: $1,000–$1,300 per month - Cost barrier for widespread access. GI side effects causing discontinuation in trials: about 5–10% - Clinical-trial tolerability estimate mentioned by Kular. Share of Americans who have been on a GLP-1 at some point: about 1 in 7 to 1 in 8 - Illustrates how widespread the medications have become. First GLP-1 medication approval year: 2005–2006 - Notes that the class has existed for two decades, though newer versions are more powerful. Eric Zimmer’s heroin addiction period before recovery: 30 years ago - Sets the timeframe of his lived-experience perspective. Eric Zimmer’s first inpatient treatment period: about 40 days - The early stage of his successful recovery program.

Pivotal Quotes: "“It is best to rise from life as from a banquet, neither thirsty nor drunken.”" — Dhruv Kular: Kular invokes Aristotle to explain moderation as the ideal but difficult modern standard. "“What happened for her was it took out alcohol noise.”" — Manoush Zomorodi describing Mary: Describes the reported reduction in obsessive thoughts about alcohol after semaglutide. "“GLP1s might be telling us that there is some type of universal pathology when it comes to addiction and that they are part of how we fix it.”" — Dhruv Kular citing a neuroscientist: Captures the hope that GLP-1s may work across different addictions.

Implications: GLP-1s could reshape addiction and obesity treatment, but the episode argues the future should be hybrid: medication plus empathy, community, and structural support. The bigger shift may be cultural—less blame, more understanding, and more realistic expectations about change.